Skip to main content
Erschienen in: Arthritis Research & Therapy 2/2004

01.04.2004 | Commentary

Measuring effectiveness of drugs in observational databanks: promises and perils

verfasst von: Eswar Krishnan, James F Fries

Erschienen in: Arthritis Research & Therapy | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Observational databanks have inherent strengths and shortcomings. As in randomized controlled trials, poor design of these databanks can either exaggerate or reduce estimates of drug effectiveness and can limit generalizability. This commentary highlights selected aspects of study design, data collection and statistical analysis that can help overcome many of these inadequacies. An international metaRegister and a formal mechanism for standardizing and sharing drug data could help improve the utility of databanks. Medical journals have a vital role in enforcing a quality checklist that improves reporting.
Literatur
1.
Zurück zum Zitat Menard HA, Beaudet F, Davis P, Harth M, Percy JS, Russell AS, Thompson JM: Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol Suppl. 1982, 8: 179-183.PubMed Menard HA, Beaudet F, Davis P, Harth M, Percy JS, Russell AS, Thompson JM: Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol Suppl. 1982, 8: 179-183.PubMed
2.
Zurück zum Zitat Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL: Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986, 81: 565-578. 10.1016/0002-9343(86)90539-5.CrossRefPubMed Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL: Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med. 1986, 81: 565-578. 10.1016/0002-9343(86)90539-5.CrossRefPubMed
3.
Zurück zum Zitat Pincus T: Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993, 23 (2 Suppl 1): 2-10.CrossRefPubMed Pincus T: Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993, 23 (2 Suppl 1): 2-10.CrossRefPubMed
4.
Zurück zum Zitat Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990, 33: 1449-1461.CrossRefPubMed Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990, 33: 1449-1461.CrossRefPubMed
5.
Zurück zum Zitat Anon: Epidemiology and randomized clinical trials [editorial]. Epidemiology. 2003, 14: 2-10.1097/00001648-200301000-00002.CrossRef Anon: Epidemiology and randomized clinical trials [editorial]. Epidemiology. 2003, 14: 2-10.1097/00001648-200301000-00002.CrossRef
6.
Zurück zum Zitat Krishnan E, Fries JF: Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med. 2003, 115: 371-376. 10.1016/S0002-9343(03)00397-8.CrossRefPubMed Krishnan E, Fries JF: Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med. 2003, 115: 371-376. 10.1016/S0002-9343(03)00397-8.CrossRefPubMed
8.
Zurück zum Zitat Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 484-489.PubMed Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T, Eberhardt K, Kvien TK, Symmons D, Silman A, van Riel P, Tugwell P, Boers M: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 484-489.PubMed
9.
Zurück zum Zitat Silman A, Symmons D: Reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 481-483.PubMed Silman A, Symmons D: Reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999, 26: 481-483.PubMed
10.
Zurück zum Zitat Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol. 1999, 150: 327-333.CrossRefPubMed Joffe MM, Rosenbaum PR: Invited commentary: propensity scores. Am J Epidemiol. 1999, 150: 327-333.CrossRefPubMed
11.
Zurück zum Zitat Wolfe F, Pincus T: Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999, 42: 1797-1808. 10.1002/1529-0131(199909)42:9<1797::AID-ANR2>3.0.CO;2-Q.CrossRefPubMed Wolfe F, Pincus T: Listening to the patient: a practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999, 42: 1797-1808. 10.1002/1529-0131(199909)42:9<1797::AID-ANR2>3.0.CO;2-Q.CrossRefPubMed
12.
Zurück zum Zitat Fries JF, Williams CA, Singh G, Ramey DR: Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol. 1997, 24: 838-844.PubMed Fries JF, Williams CA, Singh G, Ramey DR: Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. J Rheumatol. 1997, 24: 838-844.PubMed
13.
Zurück zum Zitat Moses LE: Measuring effects without randomized trials? Options, problems, challenges. Med Care. 1995, 33 (4 Suppl): AS8-AS14.PubMed Moses LE: Measuring effects without randomized trials? Options, problems, challenges. Med Care. 1995, 33 (4 Suppl): AS8-AS14.PubMed
14.
Zurück zum Zitat Rennie D: How to report randomized controlled trials. The CONSORT statement [editorial]. JAMA. 1996, 276: 649-10.1001/jama.276.8.649.CrossRefPubMed Rennie D: How to report randomized controlled trials. The CONSORT statement [editorial]. JAMA. 1996, 276: 649-10.1001/jama.276.8.649.CrossRefPubMed
Metadaten
Titel
Measuring effectiveness of drugs in observational databanks: promises and perils
verfasst von
Eswar Krishnan
James F Fries
Publikationsdatum
01.04.2004
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 2/2004
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1151

Weitere Artikel der Ausgabe 2/2004

Arthritis Research & Therapy 2/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.